CXCL10 and amyotrophic lateral sclerosis: Clinical trials have been carried out on antibodies targeting CXCL10 or CD14 in other inflammatory diseases, including rheumatoid arthritis (68), amyotrophic lateral sclerosis (69), and COVID-19 (70).